Xiaofeng Wang

This inventor holds 12 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Gmax Biopharm LLC, Alibaba Group Holding Limited, Gmaz Biopharm LLC. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiaofeng Wang. Retrieved from https://idiyas.com/inventor/xiaofeng-wang-nn4c480g

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 3)

% Patents Active = 91.7

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 9)

Average Co-Inventor Count = 4.3

ph-index = 1

Forward Citations = 2(Granted Patents)

Location History:

Hangzhou, CN (2018 - 2023)
Zhejiang, CN (2023)

Company Filing History:

Alibaba Group Holding Limited

Hangzhou Enmu Trade Co., Ltd.

patent

Years Active: 2018-2026

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12594334 - ETAR ANTIBODY, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF (2026-04-07),

2. 12473369 - FUSION PROTEIN OF ANTI-ETA ANTIBODY AND TGF-BETA TRAP AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF IN METHOD OF TREATMENT (2025-11-18),

3. D1076834 - Switch (2025-05-27),

4. 12221488 - APJ antibody, fusion protein thereof with Elabela, and pharmaceutical compositions and use thereofus01 (2025-02-11),

5. 11780916 - GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof (2023-10-10),

6. 11712470 - Human endothelin receptor antibody and use thereof (2023-08-01),

7. 11542336 - GCGR antibody and GLP-1 fusion protein thereof, pharmaceutical composition thereof and application thereof (2023-01-03),

8. 10869927 - Human endothelin receptor antibody and use thereof (2020-12-22),

9. 10376581 - Human endothelin receptor antibody and use thereof (2019-08-13),

10. 10375048 - User identity verification method and system, and verification server (2019-08-06),

11. 10253103 - Antibody specifically binding to GLP-1R and fusion protein thereof with GLP-1 (2019-04-09),

12. 10059773 - Antibody specifically binding to GLP-1 R and fusion protein thereof with GLP-1 (2018-08-28),

Title: Innovations and Contributions of Inventor Xiaofeng Wang

Introduction

Xiaofeng Wang is a prominent inventor based in Hangzhou, China. He has made significant contributions to the field of biotechnology, particularly in the development of pharmaceutical compositions. With a total of 10 patents to his name, Wang's work has the potential to impact the treatment of various cardiovascular conditions.

Latest Patents

One of Xiaofeng Wang's latest patents is focused on a switch - APJ antibody and its fusion protein with Elabela. This patent outlines a pharmaceutical composition that includes a fusion protein with the APJ antibody and Elabela. The invention aims to treat, prevent, or alleviate symptoms associated with pulmonary arterial hypertension, pulmonary hypertension, and heart failure.

Career Highlights

Throughout his career, Xiaofeng Wang has worked with notable companies such as Gmax Biopharm LLC and Hangzhou Enmu Trade Co., Ltd. His experience in these organizations has allowed him to develop innovative solutions in the pharmaceutical industry.

Collaborations

Xiaofeng Wang has collaborated with several professionals in his field, including Cheng Zhang and Shuqian Jing. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Xiaofeng Wang's contributions to biotechnology and his innovative patents demonstrate his commitment to improving healthcare solutions. His work continues to pave the way for advancements in the treatment of cardiovascular diseases.

Profile summary based on public USPTO records.